According to filings with the U.S. Securities and Exchange Commission, Hemanext is raising up to $24,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Hemanext
Hemanext is a medical technology company with headquarters and R&D Center of Excellence in Lexington MA, and manufacturing operations in Avon MA. Hemanext is committing its resources to the continuing effort of the transfusion medicine community to save lives and improve patient outcomes. Our distinctive focus is on innovations in systems enabling blood collection, processing, storage and transfusion that will promote dramatic improvements in transfusion therapies.

To learn more about Hemanext, visit https://hemanext.com/
Hemanext Linkedin Page: https://www.linkedin.com/company/hemanext/

Contact:
Eric Newman, Chief Financial Officer
781-301-7463
https://www.linkedin.com/in/eric-newman-56ab071/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.